Clinical Trials in Xiamen, China
95 recruiting
Showing 1–20 of 311 trials
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled265 locationsNCT05552222
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled283 locationsNCT06966700
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled248 locationsNCT06852222
Recruiting
Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled183 locationsNCT07190209
Recruiting
Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease
Takeda268 enrolled193 locationsNCT06233461
Recruiting
Phase 3
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
Small for Gestational Age
Xiamen Amoytop Biotech Co., Ltd.141 enrolled49 locationsNCT07309562
Recruiting
Phase 1Phase 2
A Study of ZL-1310 in Participants With Selected Solid Tumors
Solid Tumors
Zai Lab (Shanghai) Co., Ltd.112 enrolled21 locationsNCT06885281
Recruiting
Phase 2Phase 3
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Crohn Disease
Janssen Research & Development, LLC1,092 enrolled358 locationsNCT07196722
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled207 locationsNCT06422143
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche425 enrolled173 locationsNCT06819891
Recruiting
Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Cervical Cancer
Merck Sharp & Dohme LLC686 enrolled240 locationsNCT06459180
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled218 locationsNCT06170788
Recruiting
Phase 3
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University212 enrolled12 locationsNCT03907826
Recruiting
Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Endometrial Cancer
Merck Sharp & Dohme LLC1,123 enrolled248 locationsNCT06952504
Recruiting
Phase 2
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Zenith Epigenetics200 enrolled31 locationsNCT04986423
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled277 locationsNCT07063745
Recruiting
Phase 3
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Kidney Disease
Takeda347 enrolled153 locationsNCT06963827
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled233 locationsNCT06935357
Recruiting
Phase 3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Primary Membranous Nephropathy
Biogen180 enrolled93 locationsNCT06962800
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled258 locationsNCT06841354